Lilly again beats revenue estimates, raises full-year guidance

For the second consecutive quarter, Eli Lilly and Co. (NYSE:LLY) beat consensus revenue estimates and raised its full-year guidance. In its 2Q18 earnings released Tuesday, the pharma reported revenues of $6.4 billion, up 9% from $5.8 billion in 2Q17 and ahead of the Street's $6.1 billion figure. Non-GAAP EPS were $1.50, topping the $1.30 consensus.

Revenues were buoyed by stronger-than-expected sales of several products, including diabetes drugs Humalog insulin lispro and Trulicity dulaglutide, oncology drug Erbitux cetuximab and neurology product Cymbalta duloxetine. Together, the four accounted for about $1.9 billion in sales, about 10% above estimates...